Esperion Therapeutics Reports Strong Q4 and Full-Year 2025 Financial Results: Revenue Growth, Profitability, and Key Business Updates

Esperion Therapeutics, Inc. (NASDAQ: ESPR) released its financial results for the fourth quarter and full year ended December 31, 2025, offering significant insights and developments that may have a material impact on the company’s share price.

Key Financial Highlights

• Full Year 2025 Total Revenue: \$403.1 million, representing growth of 21% year-over-year (Y/Y).
• Full Year 2025 U.S. Net Product Revenue: \$159.6 million, a 47% Y/Y increase.
• Q4 2025 U.S. Net Product Revenue: \$43.7 million, up approximately 38% Y/Y.
• Q4 2025 Total Revenue: \$168.4 million, an impressive 144% Y/Y increase.
• Royalty Revenue in Q4 2025: \$14.6 million, up 51% Y/Y though down 11% sequentially.
• Cash and Cash Equivalents: \$167.9 million as of December 31, 2025, compared to \$144.8 million at the end of 2024.
• Net Income (Loss) Per Share: Q4 2025 basic and diluted net income per share were \$0.26 and \$0.22, respectively. For the full year 2025, basic and diluted net loss per share was \$0.11. This compares favorably to the prior year’s losses of \$0.11 (Q4 2024) and \$0.28 (full year 2024).
• Operating Expenses Guidance for 2026: Expected to be in the range of \$225 million to \$255 million, including approximately \$15 million in non-cash stock compensation expenses.

Operational and Strategic Highlights

• Bempedoic Acid Milestone: Received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines, a significant validation for the company’s flagship product in the cardiovascular space.
• European Expansion: Secured regulatory and reimbursement approval for NILEMDO in France, one of Europe’s largest markets, which is a major step forward in expanding the company’s ex-U.S. revenue base.
• Increase in SG&A Expenses: Selling, general and administrative (SG&A) expenses for Q4 and full year 2025 were \$41.4 million and \$165.8 million, up 12% and 2% respectively from 2024, primarily due to increased legal costs related to ANDA litigation.

Balance Sheet and Capital Structure

• Working Capital: \$161.8 million as of December 31, 2025, up from \$91.8 million a year earlier.
• Total Assets: \$465.9 million at year end, up from \$343.8 million in 2024.
• Royalty Sale Liability: \$295.8 million as of December 31, 2025.
• Convertible Notes (Net): \$97.3 million, decreased from \$151.3 million at prior year-end.
• Long-term Debt: \$152.2 million, up from \$141.0 million in 2024.
• Accumulated Deficit: \$(1.62) billion at year end, slightly higher than \$(1.60) billion in 2024.
• Shares Outstanding: 245.2 million common shares, excluding 2.0 million treasury shares.

2026 Outlook

• Esperion projects operating expenses for 2026 in the range of \$225 million to \$255 million, including about \$15 million in non-cash stock compensation.

Important Shareholder Considerations & Potential Share Price Catalysts

• Top-line Growth: The significant increases in revenue and U.S. net product sales signal strong commercial execution and market uptake, especially in the cardiovascular space.
• Profitability Progress: Achieving positive net income per share for Q4 2025 (\$0.26 basic, \$0.22 diluted) is a notable inflection compared to prior losses, and may positively influence investor sentiment and share price.
• Cash Position: Growth in cash and equivalents to \$167.9 million provides a buffer for ongoing operations and strategic flexibility.
• European Market Access: Newly secured reimbursement in France for NILEMDO can drive material ex-U.S. revenue growth, serving as a key catalyst for future financial performance.
• Bempedoic Acid Endorsement: The high-level recommendation in the ESC/EAS guidelines enhances the product’s competitive position and could boost prescriber demand and payer coverage.
• Litigation Costs: Elevated SG&A expenses from ongoing ANDA litigation may be a headwind, but resolution of legal matters could be a future catalyst.

Other Considerations

• There are no indications of written communications, soliciting material, or tender offer communications in this filing, focusing the news on operational and financial performance rather than M&A or extraordinary events.
• The company is not classified as an emerging growth company.

Conclusion

Esperion delivered robust revenue growth, improved profitability, and expanded its European presence in 2025. The transition to quarterly profitability, coupled with major regulatory milestones and a solid cash position, could all be viewed as price-sensitive developments likely to impact the company’s share value. Shareholders should closely monitor the continued commercialization of bempedoic acid, the rollout in France, and the company’s progress toward sustained profitability in 2026.

Disclaimer: This article is based on the company’s official SEC filing and associated press release. The content is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

View Esperion Therapeutics, Inc. Historical chart here